NTQ6179 not checked

Nanjing Chia-tai Tianqing Pharmaceutical

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
1 active
1 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“NTQ6179 tablets, an oral non-peptide small-molecule somatostatin receptor subtype 2 (SSTR2) agonist, administered orally as a single dose with approximately 240 milliliters (mL) of water under fasting conditions (at least 10 hours of overnight fasting prior to dosing).”In the company’s words, NCT07909837 on ClinicalTrials.gov
Tested for
Acromegaly
Main trialPhase 1
“This is a phase 1, randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, and pharmacokinetics/pharmacodynamics (PK/PD) of single oral doses of NTQ6179 tablets in healthy participants. A total of 56 healthy participants will be enrolled in 7 sequential dose cohorts, with an allocation ratio of NTQ6179 to placebo of 6:2 in each cohort.”In the company’s words, NCT07909837 on ClinicalTrials.gov

Other drugs for Acromegaly

All 2 drugs for Acromegaly

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Recruiting Apr 2027 A Phase 1 Clinical Trial of NTQ6179 Tablets in Healthy Volunteers
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow NTQ6179

Following is part of Solo: you see every change to NTQ6179 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in